Impact of Direct-Acting Antiviral Therapy on Liver Fibrosis Regression among People with Chronic HCV Infection: Results from a Real-Life Cohort in Patients Who Achieved Sustained Virological Response

Background and Objectives: The global prevalence of chronic hepatitis C virus (HCV) infection is 0.8%, affecting around 58 million people worldwide. Treatment with DAAs reduces all-cause HCV mortality by 49–68%. This work aims to determine whether there is liver fibrosis regression (LFR) in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Ros, Alejandro, Morán, Senador, Núñez, Virginia, García-Ros, Gonzalo, Ruiz, Guadalupe, García-Solano, José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141631/
https://www.ncbi.nlm.nih.gov/pubmed/37109770
http://dx.doi.org/10.3390/medicina59040814

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141631/
https://www.ncbi.nlm.nih.gov/pubmed/37109770
http://dx.doi.org/10.3390/medicina59040814

Ejemplares similares